Q-omics provides the consensus-scored PRDX5 profile across patient tissues and cancer cell-line models. PRDX5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRDX5 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, PRDX5 protein abundance shows 25,491 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LIHC, and LSCC as cancer lineages where PRDX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDX5 survival associations across molecular data types. PRDX5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDX5 RNA expression–survival associations across cancer types. High PRDX5 expression shows unfavorable associations in UVM, LIHC, BRCA and KICH, but favorable associations in OV and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PRDX5 RNA expression.
This table summarizes PRDX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PRDX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDX5 shows lower tumor expression in LUAD and higher tumor expression in LIHC, BLCA, KIRP, HNSC and CHOL. The LIHC box plot shows higher PRDX5 RNA expression in tumor versus normal tissue (log2 FC = +1.053, t-test p < 0.001).
This table shows molecular features associated with PRDX5 in patient tissues and cancer cell lines. In patient samples, PRDX5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
